Brookline Capital Markets Assumes Oncternal Therapeutics (ONCT) at Buy
Tweet
Share
E-mailGet Alerts ONCT Hot Sheet
Price: $0.53 --0%
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Brookline Capital Markets analyst Kemp Dolliver assumes coverage on Oncternal Therapeutics (NASDAQ: ONCT) with a Buy rating and a price target of $6.00.
For an analyst ratings summary and ratings history on Oncternal Therapeutics click here. For more ratings news on Oncternal Therapeutics click here.
Shares of Oncternal Therapeutics closed at $1.03 yesterday.
You May Also Be Interested In
- Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
- Lucid Capital Markets Starts SS Innovations Int'l (SSII) at Buy
- Goldman Sachs Upgrades Plains All American (PAA) to Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
